Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9ClN4 |
Molecular Weight | 196.637 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)N\N=C\C1=CC=CC=C1Cl
InChI
InChIKey=PDWJALXSRRSUHR-LFYBBSHMSA-N
InChI=1S/C8H9ClN4/c9-7-4-2-1-3-6(7)5-12-13-8(10)11/h1-5H,(H4,10,11,13)/b12-5+
Molecular Formula | C8H9ClN4 |
Molecular Weight | 196.637 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25859045Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27353344 | https://www.google.com/patents/WO2014108520A1
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25859045
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27353344 | https://www.google.com/patents/WO2014108520A1
Sephin1 is a guanabenz derivative that binds to and inhibits a regulatory subunit of the stress-induced protein phosphatase 1 (PPP1R15A), but not the constitutive PPP1R15B, and lacks beta2-adrenergic activity. Phosphorylation of eIF2α, α subunit of eukaryotic translation initiation factor 2, reduces protein synthesis and prevents the accumulation of misfolded protein in the endoplasmic reticulum (ER). PPP1R15A recruits the serine/threonine-protein phosphatase PP1 to dephosphorylate eIF2α, so inhibiting PPP1R15A activity prolongs the phosphorylation of eIF2α and aids in its prevention of the accumulation of misfolded protein. In vitro, Sephin1 protected cells from lethal protein misfolding and cytotoxic ER stress. In vivo Sephin1 prevented Charcot-Marie-Tooth 1B and ALS diseases in mice.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O75807 Gene ID: 23645.0 Gene Symbol: PPP1R15A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25859045 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25859045
Mice were treated orally with Sephin1 (1 mg/kg) or vehicle twice a day, from postnatal days 28 to 61.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25859045
Cells were plated in 24-well plates at a density of 15,000 (HeLa) or 12,000 cells/ml (MEFs) 24 hours prior to treatment. ER stress was elicited by addition of fresh media containing 2.5 µg/ml tunicamycin (Sigma-Aldrich). Sephin1 were dissolved in DMSO and added at 50mkM. Cell viability was assessed by measuring the reduction of WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4- nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] into formazan using Cell viability Counting Kit-8 (Dojindo) according to the supplier’s recommendation, 48 hours after tunicamycin treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:44:44 GMT 2023
by
admin
on
Sat Dec 16 12:44:44 GMT 2023
|
Record UNII |
9M998304JB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
868321
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9561611
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
11189
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
9M998304JB
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
951441-04-6
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
13098-73-2
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
C174585
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
300000023891
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY | |||
|
65390
Created by
admin on Sat Dec 16 12:44:44 GMT 2023 , Edited by admin on Sat Dec 16 12:44:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Scientific Literature
|
||
|
SALT/SOLVATE -> PARENT |